Jacqulyne Robichaux

3.0k total citations
26 papers, 275 citations indexed

About

Jacqulyne Robichaux is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jacqulyne Robichaux has authored 26 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jacqulyne Robichaux's work include Lung Cancer Treatments and Mutations (21 papers), HER2/EGFR in Cancer Research (10 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jacqulyne Robichaux is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), HER2/EGFR in Cancer Research (10 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jacqulyne Robichaux collaborates with scholars based in United States, Japan and South Korea. Jacqulyne Robichaux's co-authors include John V. Heymach, Yasir Y. Elamin, Marcelo V. Negrão, Xiuning Le, Jianjun Zhang, John W. Fuseler, Ann F. Ramsdell, Anne S. Tsao, George R. Blumenschein and Vincent K. Lam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Jacqulyne Robichaux

23 papers receiving 273 citations

Peers

Countries citing papers authored by Jacqulyne Robichaux

Since Specialization

Citations

This map shows the geographic impact of Jacqulyne Robichaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqulyne Robichaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqulyne Robichaux more than expected).

Fields of papers citing papers by Jacqulyne Robichaux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqulyne Robichaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqulyne Robichaux. The network helps show where Jacqulyne Robichaux may publish in the future.

Co-authorship network of co-authors of Jacqulyne Robichaux

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqulyne Robichaux. A scholar is included among the top collaborators of Jacqulyne Robichaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqulyne Robichaux. Jacqulyne Robichaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA77 FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), Jiang Zhu, Chee Khoon Lee, Isamu Okamoto, (unknown), S-W. Kim, (unknown), Igor Andrašina, (unknown), (unknown), (unknown), (unknown), Jacqulyne Robichaux, (unknown), Edgar Monterroso, Muna Albayaty, (unknown)	0
2	1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC 2025 ·Annals of Oncology ·Edurne Arriola, Jacqulyne Robichaux, Vang Quy Le, Takehiro Inoue, Nopadol Soparattanapaisarn, Chung‐Li Wang, Jarin Chindaprasirt, (unknown), Fedor Moiseenko, (unknown), (unknown), Thu H. Le, (unknown), (unknown), Ana Bolanos, (unknown), (unknown)	0
3	OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC 2025 ·Journal of Thoracic Oncology ·Collin M. Blakely, Jacqulyne Robichaux, (unknown), (unknown), Kyung‐Yul Lee, Nguyen Viet Nhung, (unknown), Jamie E. Chaft, Jiaxi He, W. Weder, (unknown), (unknown), Carles Escriu, (unknown), Preetida J. Bhetariya, Bala Swaminathan, Yuri Rukazenkov, (unknown), Maximilian J. Hochmair	1
4	Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations 2025 ·Cancer Research ·Yuji Shibata, Monique B. Nilsson, Hibiki Udagawa, Jacqulyne Robichaux, Junqin He, Xiaoxing Yu, John V. Heymach	0
5	Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, К. К. Лактионов, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung‐Ju Ahn, M. Pérol, Ryan J. Hartmaier, Jacqulyne Robichaux, Preetida J. Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, (unknown), Roy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu	15
6	MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed 2024 ·Journal of Thoracic Oncology ·(unknown), Jacqulyne Robichaux, (unknown), (unknown), Chee Khoon Lee, (unknown), (unknown), (unknown), Seung‐Whan Kim, (unknown), (unknown), Preetida J. Bhetariya, (unknown), Yuri Rukazenkov, (unknown), (unknown)	9
7	Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed 2024 ·Cancer Research ·Pasi A. Jänne, Kunihiko Kobayashi, Jacqulyne Robichaux, Chee Khoon Lee, Shunichi Sugawara, Tsung‐Ying Yang, Tae Min Kim, Noriko Yanagitani, Sang‐We Kim, Aleksandra Markovets, Preetida J. Bhetariya, Lynne Poole, Dana Ghiorghiu, Ryan J. Hartmaier, James Chih‐Hsin Yang, David Planchard	13
8	1377P Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity 2023 ·Annals of Oncology ·Xiuning Le, Jacqulyne Robichaux, Monique B. Nilsson, (unknown), (unknown), Jia Wu, Yasir Y. Elamin, Lingzhi Hong, Hibiki Udagawa, Mark A. Socinski, Gajanan Bhat, François Lebel, Sylvie Vincent, Veronica Bunn, (unknown), John W. Lawson, Jason B. Cross, John V. Heymach	2
9	HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies 2023 ·Journal of Thoracic Oncology ·Hibiki Udagawa, Monique B. Nilsson, Jacqulyne Robichaux, Junqin He, Alissa Poteete, Hong Jiang, Simon Heeke, Yasir Y. Elamin, Yuji Shibata, Shingo Matsumoto, Kiyotaka Yoh, Shogo Okazaki, Takashi Masuko, Igor Odintsov, Romel Somwar, Marc Ladanyi, Kōichi Goto, John V. Heymach	9
10	514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2 2023 ·Annals of Oncology ·Chee Khoon Lee, Jacqulyne Robichaux, Pasi A. Jänne, S-W. Kim, (unknown), Kunihiko Kobayashi, David Planchard, (unknown), Noriko Yanagitani, (unknown), (unknown), (unknown), (unknown), Yuri Rukazenkov, Ryan J. Hartmaier, James Chih‐Hsin Yang	10
11	Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial 2021 ·Journal of Clinical Oncology ·Yasir Y. Elamin, Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank V. Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo V. Negrão, Xiuning Le, Frank E. Mott, Jianjun Zhang, Lei Feng, George R. Blumenschein, Anne S. Tsao, John V. Heymach	66
12	MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) 2019 ·Journal of Thoracic Oncology ·Yasir Y. Elamin, Jacqulyne Robichaux, (unknown), Mehmet Altan, Don L. Gibbons, Frank V. Fossella, George R. Simon, Vincent K. Lam, George R. Blumenschein, Anne S. Tsao, Jonathan M. Kurie, Frank E. Mott, Marcelo V. Negrão, (unknown), Jianzhong He, Monique B. Nilsson, (unknown), Zane Yang, V. Papadimitrakopoulou, John V. Heymach	13
13	Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions. 2019 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Russell W. Madison, Jacqulyne Robichaux, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, John V. Heymach	6
14	P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Marcelo V. Negrão, Alexandre Reuben, Jacqulyne Robichaux, Xiuning Le, Monique B. Nilsson, Yasir Y. Elamin, Chang‐Jiun Wu, J. Zhang, (unknown), Emily Roarty, Waree Rinsurongkawong, Stephen G. Swisher, George R. Simon, P. Andrew Futreal, Bonnie S. Glisson, John V. Heymach	2
15	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC) 2018 ·Clinical Lung Cancer ·Yasir Y. Elamin, Daniel R. Gomez, Mara B. Antonoff, Jacqulyne Robichaux, Hai T. Tran, (unknown), (unknown), Marcelo V. Negrão, Xiuning Le, (unknown), Jeff Lewis, Lara Lacerda, Emily Roarty, Stephen G. Swisher, Jack A. Roth, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, John V. Heymach	44
16	Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients. 2018 ·Journal of Clinical Oncology ·Xiuning Le, Sonam Puri, Marcelo V. Negrão, Monique B. Nilsson, Jacqulyne Robichaux, Theresa A. Boyle, J. Kevin Hicks, Emily Roarty, Waree Rinsurongkawong, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, John V. Heymach	3
17	Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Yasir Y. Elamin, Jacqulyne Robichaux, John V. Heymach	5
18	Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants 2017 ·Cancer Research ·Jacqulyne Robichaux, Monique B. Nilsson, John V. Heymach	2
19	Left–right analysis of mammary gland development in retinoid X receptor-α ^+/− mice 2016 ·Philosophical Transactions of the Royal Society B Biological Sciences ·Jacqulyne Robichaux, John W. Fuseler, (unknown), Steven W. Kubalak, Adam Hartstone‐Rose, Ann F. Ramsdell	4
20	Mammary glands exhibit molecular laterality and undergo left–right asymmetric ductal epithelial growth in MMTV-cNeu mice* 2014 ·Oncogene ·Jacqulyne Robichaux, Robin Hallett, John W. Fuseler, John A. Hassell, Ann F. Ramsdell	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact